rupatadine has been researched along with cyproheptadine in 100 studies
| Studies (rupatadine) | Trials (rupatadine) | Recent Studies (post-2010) (rupatadine) | Studies (cyproheptadine) | Trials (cyproheptadine) | Recent Studies (post-2010) (cyproheptadine) |
|---|---|---|---|---|---|
| 116 | 43 | 62 | 2,297 | 262 | 201 |
| Protein | Taxonomy | rupatadine (IC50) | cyproheptadine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.0024 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.564 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.035 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.016 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0031 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0038 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.283 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.016 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.164 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0031 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.038 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.275 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.122 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.046 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.158 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.564 | |
| Histamine H2 receptor | Homo sapiens (human) | 0.198 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.107 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.001 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0024 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.122 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0031 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0037 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.048 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0094 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.281 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.00) | 18.2507 |
| 2000's | 33 (33.00) | 29.6817 |
| 2010's | 48 (48.00) | 24.3611 |
| 2020's | 17 (17.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Balsa, D; Ferrando, R; Forn, J; García-Rafanell, J; Giral, M; Merlos, M; Puigdemont, A; Queralt, M | 1 |
| Caballero, R; Delpón, E; Longobardo, M; Tamargo, J; Valenzuela, C | 1 |
| Brazís, P; de Mora, F; Merlos, M; Puigdemont, A; Queralt, M | 1 |
| García-Rafanell, J; Izquierdo, I; Merlos, M | 1 |
| Dumur, JP; Izquierdo, I; Pérez, I; Saint-Martin, F | 1 |
| Castillo, JA; De Molina, M; Guadaño, EM; Meseguer, J; Picado, C; Serra-Batlles, J; Valero, A | 1 |
| Barbanoj, MJ; García-Gea, C; Izquierdo, I; Jané, F; Morte, A; Pérez, I | 1 |
| Arnaiz, E; Borja, J; Conde, J; De Molina, M; Izquierdo, I; Martí-Guadaño, E; Martínez-Cócera, C; Pérez, I; Pola, J | 1 |
| Antonijoan, R; Barbanoj, MJ; Donado, E; García-Gea, C; Izquierdo, I; Jané, F; Pérez, I; Solans, A | 1 |
| Arnáiz, E; Horak, F; Izquierdo, I; Leuratti, C; Pérez, I; Stuebner, P; Zieglmayer, R | 1 |
| Picado, C | 1 |
| Cinca, J; Farré, J; Hove-Madsen, L; Llach, A; Molina, CE; Prat-Vidal, C; Roura, S | 1 |
| Camelo-Nunes, IC | 1 |
| Keam, SJ; Plosker, GL | 1 |
| Arnaiz, E; Donado, E; Gimenez-Arnau, A; Ianosi, S; Izquierdo, I; Kaszuba, A; Malbran, A; Perez, I; Poop, G; Pujol, RM | 1 |
| He, JL; Lu, J; Xu, GL; Yu, SQ; Zhang, LL; Zhou, M | 1 |
| Jolles, J; Theunissen, E; van Leeuwen, C; van Oers, A; Vuurman, E | 1 |
| Carbó, ML; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A | 1 |
| Bachert, C; Bousquet, J; Canonica, WG; Gimenez-Arnau, A; Kowalski, ML; Martí-Guadaño, E; Maurer, M; Mullol, J; Picado, C; Scadding, G; Van Cauwenberge, P | 1 |
| Nombela-Franco, L; Ruiz-Antoran, B; Silva-Melchor, L; Toquero-Ramos, J | 1 |
| Chen, Y; Liang, J; Lin, H; Tian, Y; Zhang, J; Zhang, Z | 1 |
| Agache, I; Bisbal, C; Borja, J; Donado, E; Fantin, S; Izquierdo, I; Maspero, J; Mola, O | 1 |
| da Silva Sangoi, M; da Silva, LM; Dalmora, SL; Nogueira, DR; Todeschini, V | 1 |
| Katiyar, S; Prakash, S | 1 |
| Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A | 1 |
| Fan, G; Hong, Z; Wei, H; Wen, J; Wu, Y | 1 |
| Antépara, I; Borja, J; Castillo, JA; de la Torre, F; del Cuvillo, A; Donado, E; Izquierdo, I; Molà, O; Rivas, P; Valero, A | 1 |
| Srinivas, NR | 1 |
| Armentia, A; Dueñas-Laita, A; Martín-Armentia, B; Pinacho, F; Ruiz-Muñoz, P | 1 |
| Campo, C; Carmona, R; Carvajal, A; García del Pozo, J; Gonçalves, S; Macías, D; Martín Arias, LH; Ortega, S; Pombal, R; Sáinz, M; Salado, I; Velasco, A | 1 |
| Fité-Mora, R | 1 |
| Cassano, N; Delle Donne, P; Di Leo, E; Foti, C; Nettis, E; Vacca, A; Vena, GA | 1 |
| Giménez-Arnau, A; Izquierdo, I; Maurer, M | 1 |
| Chliva, C; Clemons, A; House, M; Kalogeromitros, D; Kempuraj, D; Makris, M; Theoharides, TC; Vasiadi, M; Wolfberg, A; Zhang, B | 1 |
| Borja, J; Fité, R | 1 |
| Bartrá, J; Izquierdo, I; Mullol, J; Muñoz-Cano, R; Picado, C; Serrano, C; Valero, A | 1 |
| Ferrán, M; Giménez-Arnau, A; Izquierdo, I; Maurer, M; Metz, M; Scholz, E | 1 |
| Antonijoan, RM; Barbanoj, MJ; Donado, E; García, O; Gich, I; Izquierdo, I; Morganroth, J; Peña, J; Pérez, I; Solans, A | 1 |
| Antonijoan, RM; Ballester, MR; Barbanoj, MJ; Donado, E; García-Gea, C; Izquierdo, I; Martínez, J | 1 |
| Allala, U; Jaida, J; Maiti, R; Palani, A; Rahman, J | 1 |
| Church, MK | 1 |
| Maurer, M; Metz, M | 1 |
| Bartra, J; del Cuvillo, A; Giralt, J; Izquierdo, I; Mullol, J; Valero, A | 1 |
| Fidan, T; Fidan, V | 1 |
| Ahmed, I; Goud, P; Jaida, J; Maiti, R; Palani, A; Raghavendra, BN | 1 |
| Brummer-Korvenkontio, H; Izquierdo, I; Karppinen, A; Reunala, T | 1 |
| Baillieau, RA; Barkai, L; Doménech, A; Garde, JM; Giralt, J; Izquierdo, I; Maspero, JF; Németh, I; Nieto, A; Potter, P; Vermeulen, J | 1 |
| Bagriyanik, AH; Firinci, F; Karaman, M; Karaman, O; Kiray, M; Tuncel, T; Uysal, P; Uzuner, N; Yilmaz, O | 1 |
| Church, MK; Förtsch, A; Krause, K; Magerl, M; Martus, P; Maurer, M; Metz, M; Siebenhaar, F; Weller, K | 1 |
| Calogiuri, GF; Delle Donne, P; Di Leo, E; Ferrannini, A; Nettis, E; Vacca, A | 1 |
| Canonica, GW; Compalati, E | 1 |
| Fu, XM; Hu, ZW; Li, K; Li, Z; Lv, Q; Lv, XX; Wang, XX; Wang, ZY | 1 |
| Berger, VW; Gudehithlu, SK | 1 |
| Alevizos, M; Kalogeromitros, D; Karagkouni, A; Makris, M; Sismanopoulos, N; Theoharides, TC; Vasiadi, M | 1 |
| Dakhale, GN; Hiware, SK; Mahatme, MS; Mishra, DB; Mukhi, JI; Salve, AM; Shinde, AT | 1 |
| Braido, F; Canonica, GW; Ferrando, M; Sclifò, F | 1 |
| Carnero, L; Curto-Barredo, L; Giménez-Arnau, AM; Martinez-Escala, ME; Pujol, RM | 1 |
| Bennett, C; Carter, B; Cohen, SN; Sharma, M | 1 |
| Huang, S; Li, X; Liu, M; Xia, C; Xiong, Y; Yang, J; Yuan, Z; Zhang, H | 1 |
| Dedi, H; Goulas, A; Kalokasidis, K; Karkavelas, G; Mirtsou, V; Molyva, D; Poulios, C | 1 |
| Bachert, C; Bousquet, J; Canonica, GW; Giménez-Arnau, A; Kowalski, ML; Maurer, M; Mullol, J; Ryan, D; Scadding, G; Simons, FE | 1 |
| Badyal, DK; Johnson, M; Kwatra, G; Thomas, EA | 1 |
| Ding, L; Gu, P; Li, Q; Liu, B; Pan, L; Sun, C; Wu, C; Zhang, J | 1 |
| Abajian, M; Church, MK; Curto-Barredo, L; Giménez-Arnau, A; Izquierdo, I; Krause, K; Maurer, M; Santamaria, E | 1 |
| Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E | 1 |
| Eloy, P; Imschoot, J; Tobback, L | 1 |
| Bachert, C; González-Núñez, V; Mullol, J | 1 |
| Ferber, G; Fernandes, S; Izquierdo, I; Lorch, U; Santamaría, E; Täubel, J | 1 |
| Antonijoan, R; Campo, C; Coimbra, J; García-Gea, C; Gich, I; Labeaga, L; Puntes, M; Valiente, R | 1 |
| Chokoeva, AA; Guarneri, C; Lotti, T; Tchernev, G; Wollina, U | 1 |
| Kannappan, V; Kanthiah, S | 1 |
| Estévez, JA; Izquierdo, I; Riba, J; Santamaría, E; Valle, M | 1 |
| Ferber, G; Fernandes, S; Izquierdo, I; Santamaría, E; Täubel, J | 1 |
| Aman, SAB; Dissanayake, H; Fernando, S; Ginneliya, A; Gomes, L; Idampitiya, D; Jeewandara, C; John, AS; Madushanka, P; Malavige, GN; Ogg, GS; Paranavitane, S; Prathapan, S; Punchihewa, C; Samarasekara, S; Wanigatunga, C; Wijewickrama, A | 1 |
| Czerwinska, K; Kublin, E; Malanowic, E; Mazurek, AP; Wyszomirska, E | 1 |
| Aoki, H; Hide, M; Suzuki, T; Tanaka, A | 2 |
| Lee, JK; Simpson, RS | 1 |
| Aoki, H; Okubo, K; Suzuki, T; Tanaka, A | 1 |
| Bosma, R; Bushby, N; de Esch, IJ; de Graaf, C; Kooistra, AJ; Kuhne, S; Leurs, R; Sheppard, RJ; van den Bor, J; Vischer, HF; Wang, Z; Waring, MJ; Wijtmans, M | 1 |
| Baltodano Viales, E; Calvo Guzmán, B; Carazo Berrocal, G; Castillo Henríquez, L; Madrigal Redondo, G; Vargas Zúñiga, R | 1 |
| Didiodato, G; Gerard, L; Hopkins, S; Kotchetkov, R; McLean, J; Nay, D | 1 |
| Abdel-Hakeem, EA; Hafez, HM; Hassanein, H | 1 |
| Calvão, J; Cardoso, JC; Gonçalo, M | 1 |
| Aoki, H; Hide, M; Hirata, K; Komorita, N; Kubo, H; Suzuki, T; Tanaka, A | 1 |
| Kamiya, T; Kumagai, A; Minowa, T; Sumikawa, Y; Uhara, H | 1 |
| Theoharides, TC | 1 |
| Abdel-Lateef, MA; Almahri, A; Derayea, SM; El Hamd, MA; Samir, E | 1 |
| Mazón, Á; Nieto, A; Nieto, M | 1 |
| Antonopoulou, S; Demopoulos, C; Theoharides, TC | 1 |
| El-Ghany, SEA; Hegazy, SK; Kotkata, FAE; Mostafa, TM | 1 |
| Beyer, S; Burges, A; Chelariu-Raicu, A; Czogalla, B; Deuster, E; Hester, A; Hysenaj, I; Jeschke, U; Kahaly, M; Kolben, T; Kraus, F; Mahner, S; Mayr, D; Schmoeckel, E; Trillsch, F | 1 |
| Andronis, C; Bonacina, F; Busnelli, M; Castiglioni, S; Chiesa, G; Colombo, A; Franchi, E; Lekka, E; Manzini, S; Norata, GD; Scanziani, E | 1 |
| Khalaf, HM; Mohamed, MZ; Mohammed, HH | 1 |
| Abdalla, AM; Abdelbaky, FAF; Abdelzaher, WY; Hafez, SMNA; Khalaf, HM; Welson, NN | 1 |
| Abdel Hafez, SMN; Abdel-Gaber, SA; Abdelmonaem, AA; Hafez, HM; Ibrahim, MA; Yehia Abdelzaher, W | 1 |
| Dissanayake, H; Gangani, C; Gomes, L; Gunasinghe, D; Idampitiya, D; Jayarathna, G; Jeewandara, C; Mahapatuna, SD; Malavige, GN; Narangoda, E; Ogg, GS; Perera, Y; Prathapan, S; Sahabandu, P; Vimalachandran, V; Wanigatunga, C; Wickramanayake, S; Wijewickrama, A | 1 |
| Chen, X; Jiang, P; Liu, Y; Shi, J; Zhang, W | 1 |
16 review(s) available for rupatadine and cyproheptadine
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.
Topics: Animals; Clinical Trials as Topic; Cyproheptadine; Dose-Response Relationship, Drug; Histamine H1 Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal | 2003 |
Rupatadine: pharmacological profile and its use in the treatment of allergic disorders.
Topics: Adolescent; Adult; Animals; Cyproheptadine; Histamine H1 Antagonists; Humans; Psychomotor Performance; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria | 2006 |
New antihistamines: a critical view.
Topics: Anti-Allergic Agents; Blood-Brain Barrier; Central Nervous System Diseases; Cetirizine; Child; Cyproheptadine; Heart Diseases; Histamine H1 Antagonists, Non-Sedating; Humans; Hypersensitivity; Loratadine; Mast Cells; Piperazines; Receptors, Histamine H1; Terfenadine | 2006 |
Rupatadine: a review of its use in the management of allergic disorders.
Topics: Adolescent; Adult; Aged; Animals; Anti-Allergic Agents; Cyproheptadine; Drug Interactions; Humans; Hypersensitivity; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria | 2007 |
Rupatadine in allergic rhinitis and chronic urticaria.
Topics: Adolescent; Animals; Anti-Allergic Agents; Child; Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Dogs; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome; Urticaria | 2008 |
Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis.
Topics: Adolescent; Adult; Cyproheptadine; Histamine H1 Antagonists, Non-Sedating; Humans; Randomized Controlled Trials as Topic; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Young Adult | 2009 |
Rupatadine for the treatment of allergic rhinitis and urticaria.
Topics: Anti-Allergic Agents; Chronic Disease; Cyproheptadine; Histamine H1 Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome; Urticaria | 2011 |
Rupatadine for the treatment of urticaria.
Topics: Animals; Cyproheptadine; Histamine Antagonists; Humans; Platelet Activating Factor; Urticaria | 2013 |
Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.
Topics: Conjunctivitis, Allergic; Cyproheptadine; Histamine Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome; Urticaria | 2013 |
New therapies for allergic rhinitis.
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Benzimidazoles; Butyrophenones; Cyproheptadine; Fluticasone; Histamine H1 Antagonists; Humans; Omalizumab; Phthalazines; Piperidines; Pregnenediones; Rhinitis, Allergic; Rhinitis, Allergic, Perennial | 2014 |
H1-antihistamines for chronic spontaneous urticaria.
Topics: Cetirizine; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Loratadine; Randomized Controlled Trials as Topic; Urticaria | 2014 |
Update on rupatadine in the management of allergic disorders.
Topics: Cyproheptadine; Humans; Hypersensitivity; Platelet Activating Factor; Treatment Outcome | 2015 |
Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
Topics: Animals; Anti-Allergic Agents; Blood-Brain Barrier; Cyproheptadine; Histamine H1 Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic; Urticaria | 2016 |
The clinical evidence of second-generation H1-antihistamines in the treatment of allergic rhinitis and urticaria in children over 2 years with a special focus on rupatadine.
Topics: Adult; Child; Child, Preschool; Cyproheptadine; Histamine H1 Antagonists; Humans; Rhinitis, Allergic; Treatment Outcome; Urticaria | 2021 |
COVID-19, microthromboses, inflammation, and platelet activating factor.
Topics: Antiviral Agents; Blood Platelets; COVID-19; Cyproheptadine; Disseminated Intravascular Coagulation; Gene Expression Regulation; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Lung; Luteolin; Mast Cells; Platelet Activating Factor; Pulmonary Embolism; Quercetin; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
39 trial(s) available for rupatadine and cyproheptadine
| Article | Year |
|---|---|
A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Loratadine; Male; Middle Aged; Platelet Activating Factor; Probability; Reference Values; Rhinitis, Allergic, Seasonal; Severity of Illness Index; Treatment Outcome | 2004 |
Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Allergic Agents; Butyrophenones; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged; Piperidines; Rhinitis, Allergic, Seasonal; Severity of Illness Index; Treatment Outcome | 2004 |
Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers.
Topics: Adult; Analysis of Variance; Attention; Cross-Over Studies; Cyproheptadine; Decision Making; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Flicker Fusion; Follow-Up Studies; Histamine; Histamine H1 Antagonists; Humans; Hydroxyzine; Male; Motor Activity; Neuropsychological Tests; Pain Measurement; Platelet Activating Factor; Psychomotor Performance; Reaction Time; Self-Assessment; Skin Tests; Statistics, Nonparametric; Time Factors | 2004 |
Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Platelet Activating Factor; Rhinitis, Allergic, Seasonal; Treatment Outcome | 2005 |
Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Topics: Analysis of Variance; Central Nervous System Depressants; Cetirizine; Cognition; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Ethanol; Female; Histamine H1 Antagonists; Humans; Hydroxyzine; Male; Psychomotor Performance; Time Factors | 2006 |
Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.
Topics: Adolescent; Adult; Antigens, Plant; Cross-Over Studies; Cyproheptadine; Dactylis; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Inhalation Exposure; Male; Middle Aged; Nasal Mucosa; Placebos; Pollen; Rhinitis, Allergic, Seasonal; Sneezing | 2006 |
Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Cyproheptadine; Double-Blind Method; Female; Humans; Male; Middle Aged; Treatment Outcome; Urticaria | 2007 |
Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers.
Topics: Adult; Automobile Driving; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Hydroxyzine; Male; Middle Aged | 2007 |
Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Cyproheptadine; Female; Food-Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; Male; Tablets | 2007 |
High performance liquid chromatography-tandem mass spectrometric determination of rupatadine in human plasma and its pharmacokinetics.
Topics: Adult; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyproheptadine; Drug Stability; Estazolam; Female; Freezing; Humans; Hydrogen-Ion Concentration; Male; Molecular Structure; Quality Control; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sex Factors; Tablets; Tandem Mass Spectrometry; Time Factors | 2008 |
A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Cetirizine; Cyproheptadine; Double-Blind Method; Female; Humans; Male; Rhinitis, Allergic, Perennial; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Chromatography, High Pressure Liquid; Confidence Intervals; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; Safety; Therapeutic Equivalency | 2008 |
Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Topics: Adolescent; Adult; Aged; Child; Cyproheptadine; Electrocardiography; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Male; Medication Adherence; Middle Aged; Rhinitis, Allergic, Perennial; Spain; Time Factors; Young Adult | 2009 |
Successful treatment of chronic drug-resistant urticaria with alprazolam.
Topics: Alprazolam; Chronic Disease; Cyproheptadine; Humans; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Recurrence; Treatment Outcome; Urticaria | 2009 |
The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg.
Topics: Adult; Chronic Disease; Cyproheptadine; Dose-Response Relationship, Drug; Female; Health Surveys; Histamine H1 Antagonists, Non-Sedating; Humans; Logistic Models; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Urticaria | 2009 |
Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Allergic Agents; Cyproheptadine; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Nasal Cavity; Nasal Obstruction; Pruritus; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Rhinometry, Acoustic; Treatment Outcome | 2009 |
Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria.
Topics: Adult; Cold Temperature; Cyproheptadine; Double-Blind Method; Environmental Exposure; Female; Histamine Antagonists; Humans; Male; Middle Aged; Platelet Activating Factor; Pruritus; Treatment Outcome; Urticaria | 2010 |
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
Topics: Adolescent; Adult; Anti-Allergic Agents; Cyproheptadine; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Platelet Activating Factor; Time Factors; Young Adult | 2010 |
Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.
Topics: Adult; Central Nervous System Depressants; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Lorazepam; Male; Psychomotor Performance | 2010 |
Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety.
Topics: Adolescent; Adult; Cetirizine; Conjunctivitis, Allergic; Cyproheptadine; Eosinophils; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Immunoglobulin E; Leukocyte Count; Male; Quality of Life; Rhinitis, Allergic, Seasonal; Single-Blind Method; Young Adult | 2010 |
Rupatadine improves nasal symptoms, quality of life (ESPRINT-15) and severity in a subanalysis of a cohort of Spanish allergic rhinitis patients.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Adult; Cyproheptadine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Longitudinal Studies; Male; Nose; Prospective Studies; Quality of Life; Rhinitis, Allergic, Seasonal | 2011 |
Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety.
Topics: Adolescent; Adult; Cetirizine; Child; Chronic Disease; Cyproheptadine; Female; Follow-Up Studies; Histamine Antagonists; Humans; Male; Middle Aged; Single-Blind Method; Treatment Outcome; Urticaria; Young Adult | 2011 |
Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy.
Topics: Adult; Aedes; Animals; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Histamine H1 Antagonists; Humans; Insect Bites and Stings; Middle Aged; Placebos; Pruritus | 2012 |
Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Analysis of Variance; Anti-Allergic Agents; Argentina; Child; Cyproheptadine; Double-Blind Method; Europe; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Quality of Life; Rhinitis, Allergic; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; South Africa; Time Factors; Treatment Outcome | 2013 |
Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mastocytosis, Cutaneous; Middle Aged; Patient Satisfaction; Quality of Life; Risk Assessment; Severity of Illness Index; Spain; Treatment Outcome; Young Adult | 2013 |
Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial.
Topics: Adult; Cetirizine; Chronic Disease; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Prospective Studies; Urticaria | 2014 |
Levocetirizine and rupatadine in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Cetirizine; Child; Chronic Disease; Cyproheptadine; Female; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Platelet Activating Factor; Quality of Life; Severity of Illness Index; Tumor Necrosis Factor-alpha; Urticaria; Young Adult | 2015 |
Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.
Topics: Adult; Aged; Chronic Disease; Cold Temperature; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Remission Induction; Spain; Time Factors; Treatment Outcome; Urticaria; Young Adult | 2016 |
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
Topics: Age Factors; Child; Child, Preschool; Chronic Disease; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Hungary; Loratadine; Male; Quality of Life; Remission Induction; South Africa; Time Factors; Treatment Outcome; Urticaria | 2016 |
Rupatadine relieves allergic rhinitis: a prospective observational study.
Topics: Adult; Cyproheptadine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Prospective Studies; Quality of Life; Rhinitis, Allergic; Severity of Illness Index | 2015 |
Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Topics: Adult; Area Under Curve; Cognition; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Histamine Antagonists; Humans; Japan; Male; Placebos; Platelet Activating Factor | 2016 |
Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers.
Topics: Adult; Benzimidazoles; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Female; Healthy Volunteers; Histamine; Histamine Antagonists; Humans; Injections, Intradermal; Loratadine; Male; Piperidines; Skin | 2017 |
Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments-Comparison With the Previous White Caucasian Thorough QT Study.
Topics: Asian People; Cyproheptadine; Double-Blind Method; Electrocardiography; Food-Drug Interactions; Healthy Volunteers; Heart Rate; Humans; Long QT Syndrome; White People | 2018 |
Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Topics: Adolescent; Adult; Anti-Allergic Agents; Asian People; Child; Chronic Disease; Cyproheptadine; Double-Blind Method; Humans; Middle Aged; Treatment Outcome; Urticaria; Young Adult | 2019 |
Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Topics: Adolescent; Adult; Anti-Allergic Agents; Child; Cyproheptadine; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Rhinitis, Allergic, Seasonal; Treatment Outcome; Young Adult | 2019 |
Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.
Topics: Adolescent; Adult; Child; Chronic Urticaria; Cyproheptadine; Dose-Response Relationship, Drug; Eczema; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Japan; Male; Middle Aged; Pruritus; Severity of Illness Index; Sleepiness; Time Factors; Treatment Outcome; Young Adult | 2019 |
[USEFULNESS OF RUPATADINE FOR PRURITUS OF PATIENTS WITH ATOPIC DERMATITIS].
Topics: Cyproheptadine; Dermatitis, Atopic; Humans; Japan; Pruritus | 2020 |
Comparative study evaluating antihistamine versus leukotriene receptor antagonist as adjuvant therapy for rheumatoid arthritis.
Topics: Acetates; Adult; Arthritis, Rheumatoid; Body Mass Index; C-Reactive Protein; Clusterin; Cyclopropanes; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; E-Selectin; Egypt; Female; Histamine Antagonists; Humans; Immunosuppressive Agents; Interleukins; Leukotriene Antagonists; Male; Methotrexate; Middle Aged; Quinolines; Sulfides | 2021 |
Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial.
Topics: Animals; Cyproheptadine; Dengue; Double-Blind Method; Humans; Incidence; Mice; Severe Dengue; Treatment Outcome | 2022 |
45 other study(ies) available for rupatadine and cyproheptadine
| Article | Year |
|---|---|
Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Topics: Administration, Oral; Animals; Azepines; Blood Pressure; Cyproheptadine; Dogs; Guinea Pigs; Histamine Antagonists; Male; Mice; Motor Activity; Platelet Activating Factor; Platelet Aggregation; Pyrilamine; Rabbits; Rats; Rats, Sprague-Dawley; Triazoles | 1997 |
Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels.
Topics: Algorithms; Cyproheptadine; Electric Stimulation; Electrophysiology; Heart; Histamine H1 Antagonists; Humans; Kv1.5 Potassium Channel; Membrane Potentials; Myocardium; Patch-Clamp Techniques; Platelet Membrane Glycoproteins; Point Mutation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Receptors, Cell Surface; Receptors, G-Protein-Coupled | 1999 |
In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1.
Topics: Animals; Antibodies; Calcimycin; Cell Line; Concanavalin A; Cyproheptadine; Dogs; Histamine Antagonists; Histamine Release; Humans; Immunoglobulin E; Loratadine; Mast Cells; Skin; Thiazoles; Tumor Necrosis Factor-alpha | 2000 |
The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes.
Topics: Arrhythmias, Cardiac; Calcium; Calcium Channels, L-Type; Cyproheptadine; Electrophysiology; Histamine H1 Antagonists; Humans; Image Processing, Computer-Assisted; In Vitro Techniques; Membrane Potentials; Microscopy, Confocal; Myocytes, Cardiac; Patch-Clamp Techniques; Sarcoplasmic Reticulum; Terfenadine | 2006 |
[Protective effect of rupatadine against oleic acid-induced acute lung injury in rabbits].
Topics: Animals; Blood Gas Analysis; Bronchoalveolar Lavage Fluid; Cyproheptadine; Enzyme-Linked Immunosorbent Assay; Intercellular Adhesion Molecule-1; Interleukin-8; Lung; Male; Oleic Acid; Platelet Activating Factor; Protective Agents; Rabbits; Random Allocation; Respiratory Distress Syndrome | 2007 |
[Torsades de pointes associated with rupatadine].
Topics: Aged; Cyproheptadine; Humans; Male; Torsades de Pointes | 2008 |
Determination of rupatadine in pharmaceutical formulations by a validated stability-indicating MEKC method.
Topics: Animals; Chromatography, Micellar Electrokinetic Capillary; Cyproheptadine; Drug Stability; L Cells; Mice; Molecular Structure; Pharmaceutical Preparations; Reproducibility of Results; Sensitivity and Specificity; Tablets; Time Factors | 2008 |
Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers.
Topics: Adult; Asian People; Calibration; Chromatography, Liquid; Cyproheptadine; Drug Stability; Female; Formates; Freezing; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Methanol; Molecular Structure; Platelet Activating Factor; Quality Control; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tablets; Tandem Mass Spectrometry; Time Factors; Water; Young Adult | 2009 |
Unsuspected polymorphic metabolism of rupatadine via its primary metabolite, desloratadine.
Topics: Cyproheptadine; Cytochrome P-450 CYP3A; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Mutation; Polymorphism, Single Nucleotide | 2009 |
Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Arrhythmias, Cardiac; Cyproheptadine; Databases, Factual; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged; Odds Ratio; Portugal; Spain | 2009 |
Torsade de pointes associated with rupatadine.
Topics: Cyproheptadine; Histamine H1 Antagonists; Humans; Long QT Syndrome; Platelet Activating Factor; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Spain; Torsades de Pointes | 2009 |
Treatment of acquired cold urticaria with rupatadine.
Topics: Adult; Chronic Disease; Cold Temperature; Cyproheptadine; Female; Humans; Middle Aged; Platelet Activating Factor; Treatment Outcome; Urticaria | 2009 |
Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli.
Topics: Antibodies, Anti-Idiotypic; Cell Line, Tumor; Cells, Cultured; Cyproheptadine; Cytokines; Histamine; Histamine H1 Antagonists; Humans; Interleukin-1; Interleukin-4; Interleukin-6; Mast Cells; Stem Cell Factor; Substance P; Vascular Endothelial Growth Factor A | 2010 |
Rupatadine and heart rhythm disturbances.
Topics: Arrhythmias, Cardiac; Cyproheptadine; Humans; Platelet Activating Factor | 2010 |
[Rupatadine, oral Rupatall].
Topics: Anti-Allergic Agents; Cyproheptadine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans | 2010 |
Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males.
Topics: Administration, Oral; Adult; Area Under Curve; Cyproheptadine; Histamine; Histamine H1 Antagonists; Humans; Injections, Intradermal; Male; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Pruritus; Skin; Young Adult | 2010 |
Fixed drug eruption against rupatadine fumarate.
Topics: Adolescent; Antipruritics; Cyproheptadine; Depression; Drug Eruptions; Female; Humans | 2011 |
The effect of rupatadine on lung histopathology in a murine model of chronic asthma.
Topics: Animals; Asthma; Cyproheptadine; Disease Models, Animal; Histamine H1 Antagonists, Non-Sedating; Histocytochemistry; Lung; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Ovalbumin; Random Allocation; Specific Pathogen-Free Organisms | 2013 |
Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.
Topics: Animals; Cellular Senescence; Cyproheptadine; Lung; Male; Mice; Mice, Inbred C57BL; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Tumor Suppressor Protein p53 | 2013 |
Re: Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Letter to the editor.
Topics: Conjunctivitis, Allergic; Cyproheptadine; Histamine Antagonists; Humans; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal | 2013 |
Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor.
Topics: Anti-Allergic Agents; beta-N-Acetylhexosaminidases; Cell Line, Tumor; Cyproheptadine; Histamine; Humans; Interleukin-8; Mast Cells; Platelet Activating Factor; Substance P; Tumor Necrosis Factor-alpha | 2013 |
Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study.
Topics: Adult; Algorithms; Cold Temperature; Critical Pathways; Cyproheptadine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Sensory Thresholds; Thermosensing; Time Factors; Treatment Outcome; Urticaria | 2015 |
CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Topics: Alleles; Area Under Curve; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyproheptadine; Cytochrome P-450 CYP3A; Genotype; Humans; Male; Polymorphism, Genetic; Volunteers | 2016 |
Rupatadine effectively prevents the histamine-induced up regulation of histamine H1R and bradykinin B2R receptor gene expression in the rat paw.
Topics: Animals; Cyproheptadine; Edema; Gene Expression Regulation; Histamine; Histamine H1 Antagonists; Rats; Real-Time Polymerase Chain Reaction; Receptor, Bradykinin B1; Receptor, Bradykinin B2; Receptors, Histamine H1; Up-Regulation | 2014 |
Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study.
Topics: Chromatography, Liquid; Cyproheptadine; Female; Formates; Humans; Loratadine; Male; Plasma; Reproducibility of Results; Sensitivity and Specificity; Tablets; Tandem Mass Spectrometry | 2015 |
Trombiculiasis: not only a matter of animals!
Topics: Administration, Oral; Administration, Topical; Adult; Animals; Cyproheptadine; Diagnosis, Differential; Dogs; Drug Therapy, Combination; Fusidic Acid; Host-Parasite Interactions; Humans; Italy; Male; Triamcinolone Acetonide; Trombiculiasis; Trombiculidae | 2017 |
D-Optimal mixture design optimization of an HPLC method for simultaneous determination of commonly used antihistaminic parent molecules and their active metabolites in human serum and urine.
Topics: Anti-Allergic Agents; Chromatography, High Pressure Liquid; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Limit of Detection; Loratadine; Solid Phase Extraction; Terfenadine | 2017 |
Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.
Topics: Algorithms; Anti-Allergic Agents; Child; Child, Preschool; Computer Simulation; Cyproheptadine; Female; Humans; Male; Models, Biological; Research Design; Rhinitis, Allergic | 2017 |
A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection.
Topics: Acute Disease; Adult; Animals; Anti-Allergic Agents; Blood Platelets; Cyproheptadine; Dengue; Dengue Virus; Disease Models, Animal; Double-Blind Method; Endothelium; Female; Histamine Antagonists; Histamine H1 Antagonists, Non-Sedating; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Preliminary Data; Sri Lanka; Treatment Outcome | 2018 |
IDENTIFICATION AND DETERMINATION OF RUPATADINE AND FEXOFENADINE BY DENSITOMETRIC METHOD.
Topics: Cyproheptadine; Densitometry; Histamine H1 Antagonists; Limit of Detection; Reproducibility of Results; Terfenadine | 2016 |
Omalizumab as single-dose therapy for vernal keratoconjunctivitis.
Topics: Anti-Allergic Agents; Conjunctivitis, Allergic; Cyproheptadine; Humans; Immunoglobulin E; Keratoconjunctivitis; Male; Middle Aged; Olopatadine Hydrochloride; Omalizumab | 2019 |
Route to Prolonged Residence Time at the Histamine H
Topics: Cyproheptadine; Histamine H1 Antagonists; Humans; Kinetics; Loratadine; Molecular Docking Simulation; Protein Binding; Receptors, Histamine H1; Time Factors | 2019 |
Development of immediate release Rupatadine fumarate 10 mg tablets: A Quality by Design (QbD) approach.
Topics: Carboxymethylcellulose Sodium; Cellulose; Chemistry, Pharmaceutical; Cyproheptadine; Drug Compounding; Excipients; Fumarates; Lactose; Solubility; Starch; Stearic Acids; Tablets; Technology, Pharmaceutical | 2019 |
Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications.
Topics: Acetaminophen; Acetates; Adult; Aged; Aged, 80 and over; Cyclopropanes; Cyproheptadine; Diphenhydramine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoproliferative Disorders; Male; Middle Aged; Premedication; Quinolines; Rituximab; Standard of Care; Sulfides; Treatment Outcome | 2020 |
Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats.
Topics: Animals; Blood Glucose; Cyclin-Dependent Kinase Inhibitor p21; Cyproheptadine; Cystatin C; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Histamine Antagonists; Kidney; Male; Oxidative Stress; Platelet Activating Factor; Rats; Streptozocin; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2020 |
Fixed drug eruption to rupatadine with positive patch tests on non-lesional skin.
Topics: Cyproheptadine; Drug Eruptions; Histamine H1 Antagonists; Humans; Male; Middle Aged; Patch Tests; Recurrence; Rhinitis, Allergic | 2020 |
Two cases of angioedema without wheals induced by exercising or bathing.
Topics: Adolescent; Angioedema; Biomarkers; Complement System Proteins; Cyproheptadine; Disease Management; Disease Susceptibility; Exercise; Female; Humans; Phenotype; Self Care; Skin; Skin Tests; Treatment Outcome; Young Adult | 2020 |
Potential association of mast cells with coronavirus disease 2019.
Topics: Cell Communication; Cholecalciferol; COVID-19; COVID-19 Drug Treatment; Cromolyn Sodium; Cyproheptadine; Cytokines; Famotidine; Histamine; Histamine Antagonists; Humans; Lung; Luteolin; Macrophages; Mast Cells; SARS-CoV-2; Severity of Illness Index; Substance P | 2021 |
Resonance Rayleigh scattering and spectrofluorimetric approaches for the selective determination of rupatadine using erythrosin B as a probe: application to content uniformity test.
Topics: Cyproheptadine; Erythrosine; Indicators and Reagents; Scattering, Radiation; Spectrometry, Fluorescence; Tablets | 2021 |
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyproheptadine; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovary; Platelet Activating Factor; Platelet Membrane Glycoproteins; Prognosis; Receptors, G-Protein-Coupled; Signal Transduction; Treatment Outcome | 2021 |
Rupatadine Treatment Is Associated with Atherosclerosis Worsening and Altered T Lymphocyte Recruitment.
Topics: Atherosclerosis; Cyproheptadine; Double-Blind Method; Humans; T-Lymphocytes | 2022 |
Therapeutic effect of rupatadine against l-arginine-induced acute pancreatitis in rats: role of inflammation.
Topics: Amylases; Animals; Anti-Inflammatory Agents; Arginine; Caspase 3; Cyproheptadine; Gene Expression; Histamine Antagonists; Inflammation; Inflammation Mediators; Male; NF-kappa B; Oxidative Stress; Pancreatitis; Rats, Wistar | 2022 |
Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cyproheptadine; Fluorouracil; Heme Oxygenase-1; Liver; Male; Oxidative Stress; Platelet Activating Factor; Rats | 2022 |
Rupatadine ameliorated ulcerative colitis in rats via modulation of platelet-activatiweng factor/interleukin-6/vascular endothelial growth factor signalling pathway.
Topics: Acetic Acid; Animals; Antioxidants; Colitis, Ulcerative; Colon; Cyproheptadine; Histamine; Interleukin-6; Male; Platelet Activating Factor; Rats; Rats, Wistar; Signal Transduction; Vascular Endothelial Growth Factor A | 2022 |
Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes.
Topics: Acupuncture Points; Cyproheptadine; Diabetes Mellitus; Fumarates; Humans; Immunoglobulin E; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal | 2022 |